Search Result

Results for "

PD-1 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (186) Adenosine Receptor (1) Akt (6) AMPK (1) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (20) Aryl Hydrocarbon Receptor (3) Bacterial (1) Bcl-2 Family (1) Bcr-Abl (2) Biochemical Assay Reagents (1) Btk (2) c-Fms (3) c-Kit (2) c-Met/HGFR (1) c-Myc (2) Cadherin (1) Caspase (2) CCR (3) CD3 (1) CDK (2) CMV (1) COMT (3) COX (2) CTLA-4 (3) CXCR (7) Cyclic GMP-AMP Synthase (1) Deubiquitinase (1) DGK (7) Discoidin Domain Receptor (2) DNA/RNA Synthesis (1) EGFR (2) Endogenous Metabolite (2) Epoxide Hydrolase (1) ERK (6) Eukaryotic Initiation Factor (eIF) (1) Exosomes (1) FAAH (1) FLT3 (3) Fungal (1) FXR (1) Glycosidase (2) GSK-3 (1) HBV (3) HDAC (6) Histone Acetyltransferase (1) Histone Demethylase (2) Histone Methyltransferase (1) IFNAR (5) IGF-1R (1) IKK (1) IKZF Family (4) Indoleamine 2,3-Dioxygenase (IDO) (2) Interleukin Related (10) Itk (2) JAK (2) JNK (3) Keap1-Nrf2 (1) LAG-3 (3) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (2) LILRB (1) LRRK2 (2) MAP4K (6) MDM-2/p53 (1) METTL3 (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Molecular Glues (4) Monoamine Oxidase (9) mTOR (3) NAMPT (1) Necroptosis (1) NF-κB (2) p38 MAPK (1) PAK (1) PARP (1) PERK (1) Phosphatase (5) Phosphodiesterase (PDE) (1) PI3K (5) Potassium Channel (1) Prostaglandin Receptor (1) PROTACs (2) Ras (4) Reactive Oxygen Species (ROS) (4) Reference Standards (4) SARS-CoV (1) Sec61 (2) SHP1 (2) STAT (6) STING (3) TAM Receptor (3) Target Protein Ligand-Linker Conjugates (2) Tau Protein (1) TGF-beta/Smad (1) Tim3 (2) TNF Receptor (2) Transmembrane Glycoprotein (4) TREM receptor (1) Trk Receptor (2) TrxR (1) VEGFR (8) VISTA (2) Wee1 (2) Wnt (2) α-synuclein (5) β-catenin (2)
By Research Areas:	Cancer (232) Cardiovascular Disease (4) Infection (14) Inflammation/Immunology (83) Metabolic Disease (4) Neurological Disease (29)
Click Chemistry:	DBCO (1) Azide (1)
Oligonucleotides:	Aptamers (1) Antisense Oligonucleotides (2)

279

Inhibitors & Agonists

Screening-Bibliotheken

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: PD-1/PD-L1

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-P9902

Pembrolizumab Maximum Cited Publications 30 Publications Verification MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-19991

BMS-1 Maximum Cited Publications 31 Publications Verification PD-1/PD-L1 inhibitor 1	PD-1/PD-L1 Apoptosis	Inflammation/Immunology Cancer
BMS-1 is an inhibitor of the *PD-1/PD-L1* protein/protein interaction (IC₅₀ between 6 and 100 nM) .

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) 10+ Cited Publications	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer .

HY-P9902A

Pembrolizumab (anti-PD-1) 5 Publications Verification MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* .

HY-P9997

Rosnilimab ANB030	PD-1/PD-L1	Inflammation/Immunology
Rosnilimab (ANB030) is a *PD-1* agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high *PD-1* expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .

HY-16961

Sitravatinib 5+ Cited Publications MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting *PD-1, blocking the PD-1/PD-L1* immune checkpoint axis through competitive binding to *PD-1. Anti-Mouse PD-1* Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .

HY-P99048

Sintilimab 1 Publications Verification IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P990788

Anti-Mouse PD-1 Antibody (29F.1A12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer .

HY-108691

PF-06465469 2 Publications Verification	Itk Btk CXCR PD-1/PD-L1 LAG-3	Cancer
PF-06465469 is a covalent inhibitor of ITK with an IC₅₀ of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases *PD-1* and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma .

HY-P991628

SSGJ-707 PF-08634404	PD-1/PD-L1 VEGFR	Cancer
SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and *PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1* signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by PD-L1 expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer .

HY-102011

BMS-1166 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 is a potent *PD-1/PD-L1* immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-129600

MYCi361 2 Publications Verification NUCC-0196361	c-Myc	Cancer
MYCi361 (NUCC-0196361) is a MYC inhibitor with the K_d of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy .

HY-128679

TBK1/IKKε-IN-5	IKK	Cancer
TBK1/IKKε-IN-5 (compound 1) is an orally active TBK1 and IKKε dual inhibitor, with IC₅₀ values of 1 and 5.6 nM, respectively. TBK1/IKKε-IN-5 enhances the blockade response to *PD-1* and induces immune memory in rats when combines with anti-PD-L1. TBK1/IKKε-IN-5 can be used in cancer research, especially in tumour immunity .

HY-P99166

Vudalimab XMAB-20717	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-153358

TNG260	HDAC	Cancer
TNG260 is a selective, orally effective inhibitor of HDAC1 and CoREST complex, with a 10-fold selectivity for HDAC1 over HDAC3 and a 500-fold selectivity for CoREST complex over NuRD and Sin3 complex. TNG260 reshapes the tumor immune microenvironment, reduces immunosuppressive neutrophil infiltration, promotes effector T cell recruitment, and reverses anti-PD-1 resistance caused by STK11 deficiency by inhibiting the activity of the CoREST-HDAC1 complex. TNG260 induces durable tumor regression in combination with α-PD1 in MC38 tumor-bearing mice with STK11 mutations, and has lower toxicity to bone marrow cells than non-selective HDAC inhibitors .

HY-124447

BTYNB	IGF-1R c-Myc Apoptosis TGF-beta/Smad	Cancer
BTYNB is a structure-specific nucleic acid binder and IGF2BP1 inhibitor (with an IC₅₀ of 5 μM against hBTYNB). BTYNB disrupts the IGF2BP1-RNA interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the MYCN/IGF2BP1 loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma .

HY-128481

SB24011	STING	Inflammation/Immunology Cancer
SB24011 is a STING modulator and a TRIM29-STING protein-protein interaction inhibitor. SB24011 blocks TRIM29-induced K48-linked specific ubiquitination by binding to STING, thereby upregulating intracellular STING protein levels. SB24011 enhances inflammatory cytokine expression and STING-mediated immune responses, and exhibits abscopal antitumor activity that promotes tumor regression and activates T cell infiltration. When combined with STING agonists or anti-PD1 antibodies, SB24011 synergistically enhances antitumor responses. SB24011 is suitable for research related to colon cancer and melanoma .

HY-122542B

PPACK TFA 2 Publications Verification	Ligands for E3 Ligase Molecular Glues IKZF Family	Cardiovascular Disease
PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8 ⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with PD-L1 and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

HY-116274

BMS-8 1 Publications Verification	PD-1/PD-L1	Cancer
BMS-8 inhibits the *PD-1/PD-L1* interaction with IC₅₀ of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1 .

HY-P99345

Dostarlimab TSR-042; ANB-011; WBP-285	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-P990169

Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human phosphorylated *PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279* Antibody (407.6G12) can detect the phosphorylated form of the PD-1 ITSM by both western blot and flow cytometry .

HY-P5005

VIPhyb	CMV PD-1/PD-L1	Infection Inflammation/Immunology Cancer
VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate *PD1. VIPhyb can inhibit* cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis .

HY-138742

HPK1-IN-7	MAP4K	Cancer
HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC₅₀=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1 .

HY-P990824

Anti-Mouse PD-1 Antibody (J43) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer .

HY-P991078

Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P990690

Volrustomig MEDI-5752	PD-1/PD-L1 CTLA-4	Cancer
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting *CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1* internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 ⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 ⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Inflammation/Immunology Cancer
Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma .

HY-12964

SGI-7079 3 Publications Verification	TAM Receptor	Cancer
SGI-7079 is a selective, ATP-competitive, orally active inhibitor of the receptor tyrosine kinase Axl. SGI-7079 blocks Axl-mediated signaling pathways such as NF-κB activation and MMP-9 expression, thereby inhibiting tumor cell proliferation, migration and invasion. SGI-7079 is mainly used in the research of malignant tumors such as inflammatory breast cancer and bladder cancer, as well as in combination with immunization (used in combination with PD-1 therapy)[1][2][3].

HY-P990704

Rilvegostomig AZD-2936	PD-1/PD-L1 Transmembrane Glycoprotein	Cancer
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting *PD-1* and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer .

HY-P99916

Emirodatamab AMG-427	FLT3 CD3 TNF Receptor	Inflammation/Immunology Cancer
Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with *PD-1* blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .

HY-122542A

PPACK dihydrochloride 2 Publications Verification Pebac; D-Phenylalanyl-prolyl-arginyl Chloromethyl Ketone; D-Phe-Pro-Arg-CH2Cl	Ligands for E3 Ligase Molecular Glues IKZF Family	Cardiovascular Disease
PPACK dihydrochloride is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK dihydrochloride binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8 ⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK dihydrochloride also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK dihydrochloride can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .

HY-101058A

PD1-PDL1-IN 1 TFA	PD-1/PD-L1	Inflammation/Immunology Cancer
PD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 TFA is useful as immune modulator .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against *PD-1* that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .

HY-101097

PD-1-IN-17	PD-1/PD-L1	Cancer
PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM .

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .

HY-139616

Sec61-IN-2	Sec61 PD-1/PD-L1	Cancer
Sec61-IN-2 is a Sec61 inhibitor. Sec61-IN-2 shows a significant inhibitory effect on *PD-1* related reporter gene cell models (PD1tsGluc) (IC₅₀ = 42 nM), while it has almost no inhibitory activity in TNFα, Her3, and IL-2 pathway models. Sec61-IN-2 can be used for cancer research .

HY-144088

ZYF0033 2 Publications Verification HPK1-IN-22	MAP4K	Inflammation/Immunology Cancer
ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a ⁺CD8 ⁺ T cells, but not T cells, PD-1 ⁺CD8 ⁺ T cells, TIM-3 ⁺CD8 ⁺ Infiltration of T cells and LAG3 ⁺CD8 ⁺ T cells was reduced .

HY-P991079

Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-134886

PD-1-IN-24	PD-1/PD-L1	Cancer
PD-1-IN-24 (compound 1) is an orally active *PD-1* inhibitor .

HY-P991739

RC148	VEGFR PD-1/PD-L1	Cancer
RC148 is a humanized IgG1 bispecific antibody targeting VEGF and *PD-1. RC148 blocks PD-1-PD-L1* and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer .

HY-155101

PD-L1-IN-3	PD-1/PD-L1	Cancer
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC₅₀ value and EC₅₀ value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research .

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .

HY-159643

NDI-101150	MAP4K IFNAR Interleukin Related	Inflammation/Immunology Cancer
NDI-101150 is an orally active, potent and selective hematopoietic progenitor cell kinase 1 (HPK1) inhibitor with an IC₅₀ of 0.7 nM. NDI-101150 blocks HPK1-mediated negative regulation of immune receptor signaling, inhibits immunosuppression of T cell activation, enhances antigen-specific antibody production and augments B-cell activation. NDI-101150 inhibits tumor growth in syngeneic tumor models, establishes durable antitumor immune memory, and synergizes with anti-PD1 to enhance exhausted T cell activity and drive tumor regressions. NDI-101150 can be used for the research of cancer, such as breast cancer and colon cancer .

HY-172930

PVTX-405	Molecular Glues IKZF Family Potassium Channel	Inflammation/Immunology Cancer
PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC₅₀ of 0.7 nM and a D_max of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC₅₀ of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn ^391V C57BL/6 mice .

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 .

HY-155959

PD-1/PD-L1-IN-33	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity .

Art. -Nr.	Produktname

HY-L031

Small Molecule Immuno-Oncology Compound Library

788 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 788 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L109

Protein-protein Interaction Inhibitor Library

797 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 797 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Art. -Nr.	Produktname	Target	Research Area

HY-P10375

BMS-986189	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC₅₀ of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987 .

HY-122542B

PPACK TFA 2 Publications Verification	Ligands for E3 Ligase Molecular Glues IKZF Family	Cardiovascular Disease
PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8 ⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .

HY-P5005

VIPhyb	CMV PD-1/PD-L1	Infection Inflammation/Immunology Cancer
VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate *PD1. VIPhyb can inhibit* cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis .

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function .

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 .

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC₅₀ of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein** inhibitor with a K_d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 .

HY-103048

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 .

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P11011

Peptide R54 Pep R54; CXCR4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

HY-P10838

PL120131	PD-1/PD-L1 Apoptosis	Cancer
PL120131 is a *PD-1* antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 can be used in research related to breast cancer and various malignant tumors .

HY-P10826

PD-1/PD-L1 inhibitory peptide C8	PD-1/PD-L1	Cancer
PD-1/PD-L1 inhibitory peptide C8 is inhibits *PD-1/PD-L1* interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .

HY-P10838A

PL120131 acetate	PD-1/PD-L1 Apoptosis	Cancer
PL120131 acetate is a *PD-1* antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 acetate rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 acetate can be used in research related to breast cancer and various malignant tumors .

HY-P11490

DPMI-ω	MDM-2/p53	Inflammation/Immunology Cancer
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 ⁺/CD8 ⁺ cytotoxic T cells and suppressing CD4 ⁺/CD25 ⁺ regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .

Art. -Nr.	Produktname	Target	Research Area	Image

HY-P9902

Pembrolizumab Maximum Cited Publications 30 Publications Verification MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P99675

Ivonescimab 1 Publications Verification AK112	PD-1/PD-L1 VEGFR	Cancer
Ivonescimab (AK112) is a *PD-1/VEGF* bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) 10+ Cited Publications	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer .

HY-P9902A

Pembrolizumab (anti-PD-1) 5 Publications Verification MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* .

HY-P9997

Rosnilimab ANB030	PD-1/PD-L1	Inflammation/Immunology
Rosnilimab (ANB030) is a *PD-1* agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high *PD-1* expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting *PD-1, blocking the PD-1/PD-L1* immune checkpoint axis through competitive binding to *PD-1. Anti-Mouse PD-1* Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .

HY-P99048

Sintilimab 1 Publications Verification IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P990788

Anti-Mouse PD-1 Antibody (29F.1A12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer .

HY-P991628

SSGJ-707 PF-08634404	PD-1/PD-L1 VEGFR	Cancer
SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and *PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1* signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by PD-L1 expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer .

HY-P99166

Vudalimab XMAB-20717	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P991621

EOS006215 EOS-215	TREM receptor	Cancer
EOS006215 (EOS-215) is a humanized monoclonal antibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with PD-L1 and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

HY-P99345

Dostarlimab TSR-042; ANB-011; WBP-285	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-P990169

Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human phosphorylated *PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279* Antibody (407.6G12) can detect the phosphorylated form of the PD-1 ITSM by both western blot and flow cytometry .

HY-P99118

Serplulimab HLX 10	PD-1/PD-L1 Akt STAT	Cancer
Serplulimab (HLX 10) is a humanized *anti-PD-1* monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer .

HY-P990824

Anti-Mouse PD-1 Antibody (J43) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer .

HY-P991078

Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P990690

Volrustomig MEDI-5752	PD-1/PD-L1 CTLA-4	Cancer
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting *CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1* internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 ⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 ⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Inflammation/Immunology Cancer
Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma .

HY-P990704

Rilvegostomig AZD-2936	PD-1/PD-L1 Transmembrane Glycoprotein	Cancer
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting *PD-1* and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer .

HY-P99916

Emirodatamab AMG-427	FLT3 CD3 TNF Receptor	Inflammation/Immunology Cancer
Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with *PD-1* blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against *PD-1* that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .

HY-P990961

Palverafusp alfa IMM-2510; SYN-2510	VEGFR PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
Palverafusp alfa (IMM-2510; SYN-2510) is a PD-L1/VEGF-targeting IgG1κ type humanized antibody. Palverafusp alfa blocks PD-1/PD-L1 binding, relieves immune suppression, mediates PD-L1-directed antibody-dependent cellular cytotoxicity (ADCC). Palverafusp alfa blocks VEGF/VEGFR binding, inhibits angiogenic signaling, relieves VEGF-induced immune suppression. Palverafusp alfa reduces endothelial cell proliferation, enhances ADCC and antibody-dependent cellular phagocytosis (ADCP), inhibits tumor growth, reverses T cell immune suppression. Palverafusp alfa exhibits immune stimulatory, antiangiogenic, and anti-tumor activity in the tumor microenvironment. Palverafusp alfa can be used for the research of cancer, such as solid tumors, non-small cell lung cancer .

HY-P991481

S-531011	CCR	Inflammation/Immunology Cancer
S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8 ⁺regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma .

HY-P991079

Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P991739

RC148	VEGFR PD-1/PD-L1	Cancer
RC148 is a humanized IgG1 bispecific antibody targeting VEGF and *PD-1. RC148 blocks PD-1-PD-L1* and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer .

HY-P990828

Anti-PD-L1/B7-H1 Antibody (29E.2A3)	PD-1/PD-L1	Infection
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human PD-L1/B7-H1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can block the binding of PD-1 to PD-L1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can be used for the research of infection, such as hepatitis C virus (HCV) .

HY-P99887

Pimivalimab JTX-4014	PD-1/PD-L1	Cancer
Pimivalimab (JTX-4014) is a *PD-1* inhibitor. Pimivalimab can be used for the research of solid tumor .

HY-P99639

Geptanolimab Genolimzumab; APL-501; CBT-501; GB-226	PD-1/PD-L1	Cancer
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .

HY-P99048A

Sintilimab (Anti-PD-1) IBI308 (Anti-PD-1)	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P990170

Anti-Mouse PD-L2/B7-DC Antibody (TY25)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse PD-L2/B7-DC Antibody (TY25) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse PD-L2/B7-DC. Anti-Mouse PD-L2/B7-DC Antibody (TY25) blocks PD-L2 binding to PD-1 and blocks PD-1 signaling. Anti-Mouse PD-L2/B7-DC Antibody (TY25) can be used for the researches of inflammation and immunology, such as conjunctivitis and transplantation .

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-P990716

Sabestomig AZD7789	PD-1/PD-L1 Tim3	Inflammation/Immunology
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting *PD-1* and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma .

HY-P991356

FAZ-053 LAE-005	PD-1/PD-L1	Cancer
FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases .

HY-P992478

TY101	PD-1/PD-L1	Cancer
TY101 is an anti-PDCD1/PD-1/CD279 monoclonal antibody. TY101 binds to and inhibits PD-1 and its downstream signaling pathways .

HY-P992357

GNUV201	PD-1/PD-L1	Cancer
GNUV201 is a *PD-1* inhibitor with cross-reactivity in humans, mice and monkeys, which effectively blocks the *PD-1/PD-L1* interaction. GNUV201 activates T cells and restores their anti-tumor activity, effectively inducing tumor regression. GNUV201 can be used in the research of related diseases such as colorectal cancer, melanoma, pancreatic cancer and colon cancer .

HY-P992434

OSE-279	PD-1/PD-L1 SHP1 Interleukin Related	Cancer
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting *PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1* ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .

HY-P992177

AI-025	PD-1/PD-L1	Inflammation/Immunology Cancer
AI-025 is an anti-PD-1 antibody. AI-061, a combination formulation of AI-025 and ONC-392 (HY-P990042), inhibits the downregulation of cell activation and proliferation mediated by PD-1 and CTLA-4, thereby restoring immune function and activating cytotoxic T lymphocyte-mediated immune responses against tumor cells. AI-025 can be used in cancer research .

HY-P992062

Anti-Mouse CD80 Antibody (TKMG48)	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse CD80 Antibody (TKMG48) is an antibody that targets mouse CD80. By specifically binding to and disrupting the CD80:PD-L1 complex to release PD-L1, Anti-Mouse CD80 Antibody (TKMG48) functions as an indirect *PD-1* agonist without blocking CD28 co-stimulation or CD80-CTLA4 binding. Anti-Mouse CD80 Antibody (TKMG48) inhibits T cell activation, reduces T cell effector functions and antigen-specific CD8 ⁺ T cell populations, and does not interfere with the differentiation, migration, antigen presentation or surface marker expression of dendritic cells. Anti-Mouse CD80 Antibody (TKMG48) significantly attenuates disease severity in mouse models of arthritis, spondyloarthritis, multiple sclerosis and Sjögren's syndrome, and its activity depends on the expression of PD-1 and PD-L1 .

HY-P992448

RC98	PD-1/PD-L1	Cancer
RC98 is a monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) and acts as a selective PD-L1 inhibitor. RC98 binds specifically to human and cynomolgus monkey PD-L1. RC98 blocks the interaction between PD-L1 and its receptor PD-1 to reverse T-cell inactivation mediated by PD-1/PD-L1 signaling. RC98 enhances the cytotoxic T-lymphocyte-mediated anti-tumor immune response against PD-L1-expressing tumor cells. RC98 can be used for the research of tumor immunity and solid tumors .

HY-P992351

ELB021	Inhibitory Antibodies	Infection Cancer
ELB021 is an antibody inhibitor targeting the CD160 checkpoint. ELB021 specifically binds to CD160 on the cell surface and blocks its immune checkpoint pathway, thereby stimulating innate and adaptive anti-tumor immune responses. ELB021 effectively eliminates CD160-expressing cancer cells by enhancing T cell proliferation and CD8 ⁺ T cell-mediated cytotoxicity. Independent of *PD-1* regulation, ELB021 is applicable to research related to B-cell leukemia and HIV-1 infection .

HY-P992380

IBC-Ab002	PD-1/PD-L1	Neurological Disease
IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the *PD-1/PD-L1* pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease .

HY-P990823

Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11)	PD-1/PD-L1	Infection Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) is rat-derived IgG2b κ type antibody inhibitor, targeting to PD-L1/B7-H1. Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) can block PD-L1/ B7-1 interactions and does not block PD-L1/PD-1 interactions. Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) can be used for the researches of cancer, infection, immunology and metabolic disease, such as MB49 tumor, heart graft and diabetes .

HY-P992353

ES009	LILRB	Cancer
ES009 is a high-affinity LILRB2 antagonist, with IC₅₀ values of 14.07 nM and 18.61 nM for inhibiting hLILRB2-huANGPTL3 and hLILRB2-huANGPTL4, respectively. ES009 specifically blocks the interactions between LILRB2 and MHC class I as well as non-MHC ligands, thereby effectively inhibiting receptor activation. ES009 can reprogram anti-inflammatory myeloid cells and induce their conversion to a pro-inflammatory phenotype, and also reverse the T cell suppression mediated by macrophages. When combined with anti-PD-1 blockade therapy, ES009 synergistically enhances T cell activation. ES009 can be used in research related to advanced solid tumors and ovarian cancer .

HY-P992454

S095018	Tim3	Cancer
S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1 antibody Sym021. S095018 also induces an increase in the density of CD8 ⁺T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer .

HY-P991944

ZL-1218	CCR	Cancer
ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 ⁺ cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .

Art. -Nr.	Produktname	Category	Target	Chemical Structure

HY-N0819

Raddeanin A 1 Publications Verification	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification Cancer	Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma .

HY-N3431

Kaempferol-7-O-rhamnoside	Flavonols Flavonoids other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Chimonanthus nitens Oliv. Plants Disease Research Fields Source Classification Calycanthaceae	AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS)
Kaempferol-7-O-rhamnoside is a *PD-1/PD-L1* inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .

HY-N0460

1-Caffeoylquinic acid 1 Publications Verification	Phyllodium pulchellum (L.) Desv. Classification of Application Fields Phenols Polyphenols Plants Compositae Disease Research Fields Source Classification Cancer	NF-κB PD-1/PD-L1
1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with K_i of 0.007 μM . 1-Caffeoylquinic acid has anti-oxidative stress ability . 1-Caffeoylquinic acid is the Inhibitor for *PD-1/PD-L1* .

HY-150058

Bocconoline	Alkaloids Bocconia pearcei Plants Isoquinoline Alkaloids Papaveraceae Source Classification	Others
Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD) .

HY-N8389

Globulol	Structural Classification Terpenoids Sesquiterpenes Myrtaceae Plants Eucalyptus globulus Labill. Source Classification	Bacterial Fungal PAK Akt STAT PD-1/PD-L1 Apoptosis CCR
Globulol is a terpenoid metabolite and Antimicrobial agent. Globulol can be isolated from Alpinia oxyphylla Miq. Globulol binds to PAK4, reduces the expression level of PAK4 in cancer cells, decreases the phosphorylation of AKT, and downregulates the expressions of STAT3, phosphorylated STAT3, and PD-L1. Globulol promotes the secretion of CCL4 by cancer cells. Globulol reduces the viability and proliferation ability of cancer cells, induces G0/G1 cell cycle arrest and Apoptosis in cancer cells, and inhibits cancer cell migration and the integrity of 3D tumor spheres. Globulol enhances the relevant effects of anti-PD-1 agents in the cancer cell microenvironment. Globulol exhibits anticancer activity against liver cancer. Globulol inhibits the mycelial growth of phytopathogenic fungi and the growth of phytopathogenic bacteria. Globulol can be used in studies related to hepatocellular carcinoma .

HY-N12537

PD-1/PD-L1-IN-38	Ketones, Aldehydes, Acids Labiatae Samanea saman (Jacq.) Merr. Plants Source Classification	PD-1/PD-L1
PD-1/ PD-L1-in-38 is a *PD-1/PD-L1* inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity .

HY-N12537A

(2R,3S)-PD-1/PD-L1-IN-38	Ketones, Aldehydes, Acids Labiatae Samanea saman (Jacq.) Merr. Plants Source Classification	Aryl Hydrocarbon Receptor PD-1/PD-L1
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8 ⁺T cells and inhibits the signal transduction of PD-1/PD-L1 .

HY-N0460R

1-Caffeoylquinic acid (Standard)	Phyllodium pulchellum (L.) Desv. Structural Classification Phenols Polyphenols Plants Compositae Source Classification	Reference Standards NF-κB PD-1/PD-L1
1-Caffeoylquinic acid (Standard) is the analytical standard of 1-Caffeoylquinic acid. This product is intended for research and analytical applications. 1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with K_i of 0.007 μM . 1-Caffeoylquinic acid has anti-oxidative stress ability . 1-Caffeoylquinic acid is the inhibitor for *PD-1/PD-L1* .

HY-N0819R

Raddeanin A (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK
Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.

HY-165394

Melafolone	Structural Classification Natürliche Produkte Polygonaceae Adiantum venustum Don Plants Source Classification	COX EGFR PD-1/PD-L1 PI3K Akt
Melafolone is a potent dual COX-2/EGFR inhibitor with IC₅₀s of 13.2 μM (COX-2) and 17.4 μM (EGFR). Melafolone enhances the effect of anti-PD-1 through vascular normalization and PD-L1 downregulation via the PI3K/Akt pathway in Lewis lung carcinoma (LLC) and CMT167 models. Melafolone can be used for lung cancer research .

Art. -Nr.	Produktname		Classification

HY-169392

D5B		DBCO
D5B is a potent and selective PD-L1 inhibitor. D5B has been modified by DBCO. The EC₅₀ of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity .

HY-162356

PD-L1-IN-4		Azide
PD-L1-IN-4 (Compound X18) is an orally active PD-L1 inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer .

Art. -Nr.	Produktname		Classification

HY-160041A

Olaptesed pegol sodium NOX-A12 sodium		Antisense Oligonucleotides
Olaptesed pegol (NOX-A12) sodium is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol sodium can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol sodium can be used for researches of colon cancer and lymphocytic leukemia .

HY-160041

Olaptesed pegol NOX-A12		Antisense Oligonucleotides
Olaptesed pegol (NOX-A12) is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol can be used for researches of colon cancer and lymphocytic leukemia .

HY-177801

XQ-P3 sodium		Aptamers
XQ-P3 sodium is an aptamer that binds to PD-L1. XQ-P3 can inhibit the PD-1/PD-L1 interaction and restore the function of T cells to detect and attack tumor cells.

Online-Anfrage

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Anrede			Country or Region *
Name des Antragstellers *			Name der Organisation *
Department *
E-Mail-Addresse *			Produktname *
Art. -Nr.			Requested quantity *
Telefonnummer *
Bemerkungen